Eupraxia Research Development from 2010 to 2025
| EPRX Stock | CAD 10.02 0.02 0.20% |
Research Development | First Reported 2019-09-30 | Previous Quarter 5.2 M | Current Value 6.1 M | Quarterly Volatility 2.3 M |
Check Eupraxia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eupraxia Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 584.2 K, Interest Income of 714.5 K or Depreciation And Amortization of 176 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.02. Eupraxia financial statements analysis is a perfect complement when working with Eupraxia Pharmaceuticals Valuation or Volatility modules.
Eupraxia | Research Development |
Pair Trading with Eupraxia Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eupraxia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eupraxia Stock
The ability to find closely correlated positions to Eupraxia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eupraxia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eupraxia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eupraxia Pharmaceuticals to buy it.
The correlation of Eupraxia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eupraxia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eupraxia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eupraxia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.